Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland

Dorota Koczkodaj1, Szymon Zmorzyński1, Małgorzata Michalak-Wojnowska1, Ewa Wąsik-Szczechank2, Agata A. Filip1

1 Department of Cancer Genetics, Medical University of Lublin, Lublin, Poland
2 Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland

Submitted: 8 January 2014
Accepted: 5 April 2014

Arch Med Sci 2016; 12, 1: 120–128
DOI: 10.5114/aoms.2015.49811
Copyright © 2016 Termedia & Banach

Abstract

Introduction: Acute myeloid leukemia (AML) is a genetically heterogeneous disease at both the cytogenetic and molecular levels. In AML cells many chromosomal aberrations are observed, some of them being characteristic of a particular subtype of patients, and others being less significant. Besides chromosomal abnormalities, the leukemic cells can have a variety of mutations involving individual genes. The aim of this work was to investigate the frequencies of molecular alterations with the focus on FLT3-ITD and NPM1 mutations in AML patients of different age groups living in a southeastern region of Poland.

Material and methods: The study group comprised 50 consecutive AML patients. We analyzed bone marrow samples by conventional cytogenetics. Cytogenetic evaluation in selected cases was complemented by the FISH technique. The internal tandem mutation in the FLT3 gene was identified using polymerase chain reaction (PCR), and the NPM1 mutation was assessed by direct nucleotide sequencing.

Results: The studies using classical cytogenetics showed chromosomal aberrations in 32 (64%) patients. In 18 cases no changes in the karyotype were found by conventional karyotyping. FLT3-ITD mutation was detected in 4 (8%) patients and mutation of NPM1 in 3 patients with AML (6%).

Conclusions: The incidence of both mutations in our study group was lower than described elsewhere. We have confirmed that FLT3-ITD occurred more commonly in older patients and it was associated with shorter overall survival. By contrast, mutation of exon 12 of the NPM1 gene seems to be a good prognostic factor in AML patients with normal karyotype.

Key words: acute myeloid leukemia, FLT3-ITD, NPM1, karyotype.

Introduction

Acute myelogenous leukemia (AML) is a hematopoietic proliferative disease in which there is clonal proliferation and accumulation of morphologically and functionally immature blast cells, derived from a precursor, transformed hematopoietic marrow cells with the exception of the lymphoid lineage [1, 2]. Acute myelogenous leukemia represents 75–80% of the cases of acute leukemia in adults; in children it occurs in about 15% of all cases [1, 3].
Chromosomal instability manifested in the form of chromosomal aberrations is a classic marker of many malignancies derived from the hematopoietic system [4]. The presence of chromosomal aberrations correlates with morphological features and clinical course of leukemia [5, 6]. In 40–49% of AML patients, cryptic structural changes of chromosomes are present, undetectable by means of standard karyotyping, which results in false-negative cytogenetic test results. Patients with such a normal karyotype (cytogenetically normal AML—CN-AML) represent the largest proportion of AML and are classified in the intermediate risk group, together with carriers of t(9;11) and trisomy 8 (+8) [7]. To better characterize the prognosis in this patient group, it is important to study the FLT3 gene (locus 13q12) and NPM1 gene (locus 5q35) mutational status.

**FLT3**

The FLT3 gene encodes a receptor tyrosine kinase (fms-like tyrosine kinase 3 – FLT3). Tyrosine kinases are enzymes that direct the phosphorylation of proteins involved in cellular signal transduction. FLT3 receptors are present on the surface of early hematopoietic progenitor cells [8].

The FLT3 ligand through its FLT3 receptor plays an important role in the proliferation and differentiation of hematopoietic progenitor cells as well as in the pathogenesis of AML [4, 9]. It is mutated in about 25% of AML patients (all FAB subtypes), either by internal tandem duplications (ITD) of the juxtamembrane domain or by point mutations usually involving the kinase domain (KD) [10, 11]. Both types of mutation constitutively activate FLT3, and autophosphorylation of FLT3 receptor activates the intracellular signal pathways responsible for proliferation [9]. Many studies have shown that AML patients with FLT3-ITD mutations have poor cure rates due to relapse [12, 13].

**NPM1**

The NPM1 gene contains 12 exons that encode three isoforms of protein—nucleophosmin (NPM), a phosphoprotein with molecular weight of 37 kDa. It belongs to the chaperone protein family involved in, among other actions, the formation of ribosomes and the distribution of centromeres. It plays a key role in post-transcriptional processing of rRNA and ribosomal subunit synthesis [14, 15]. Nucleophosmin protein maintains genomic stability and controls mechanisms of DNA repair and duplication of centrosomes during mitosis [16]. NPM also interacts with tumor suppressors such as TP53 and ARF [17].

To date, about 50 mutations of the NPM1 gene have been found in AML [18]. They are the most common cryptic alterations in CN-AML, which are associated with distinct molecular, pathological and clinical characteristics. The majority of NPM1 mutations in patients with AML have a fixed location in exon 12; they are mostly insertions and deletions [19]. NPM1-mutated AML was included in the 2008 World Health Organization (WHO) classification of lympho-hemopoietic neoplasms as a provisional entity.

Identification of cryptic genome alterations allows for more precise stratification of AML patients into risk groups. This is why we decided to check for the aforementioned lesions in patients living in southeastern Poland.

**Material and methods**

The study group consisted of 50 consecutive patients (19 women and 31 men) aged between 18 and 74 years, hospitalized at the Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin in the years 2008–2012. The preliminary diagnosis of AML was based on standard FAB (French-American-British) criteria. The follow-up covered a period of 3 years (36 months).

With informed consent (approval number of the University Ethics Committee: KE-254/24/2011) the bone marrow aspirates were collected to heparin and EDTA collection tubes (Sarstedt, Germany), to be used for cell culture and for DNA isolation, respectively. Twenty-four and 72-hour unstimulated cell cultures were terminated conventionally, then GTG and RHG banded chromosomes were analyzed. Cytogenetic evaluation in selected cases was complemented by the fluorescent in situ hybridization (FISH) technique.

FISH was performed according to the manufacturer’s protocol with the probes for t(15;17)(PML/ RARA), EVI1, MYC, MLL, TP53 and a probe specific for centromeric sequences of chromosome 8 (all from Vysis, Abbott Laboratories, USA).

**Determination of the FLT3 internal tandem gene duplication**

For this purpose, PCR was performed on 150 ng of patients’ DNA with primers flanking the FLT3 gene fragment comprising exon 14 and 15 (F: 5’-GCAATTAGTATGAAAGCCACG-3’, R: 5’-CTTCAACATTTTAGCAGGAAAC-3’, Genomed, Poland) [20]. HD polymerase (2.5 U/ml) from Clontech (Clontech, USA) was used for amplification. The reaction conditions were as follows: i. initial denaturation – 95°C 5 min, ii. 35 cycles of 95°C 30 s, 66°C 30 s, 72°C 30 s, iii. final elongation – 72°C 5 min. The resulting PCR product was electrohoresed in 3.5% agarose gel at 7.5 V/cm for about 60 min.
**NPM1** mutation status study

The determination of all possible mutations in exon 12 of the NPM1 gene was performed using direct sequencing. Primer sequences were selected and the procedure of sequencing was performed according to Döhner et al. [21], except for modified thermal conditions of the first PCR reaction aimed at amplifying the template for sequencing reactions: i. initial denaturation – 95°C 5 min, ii. 35 cycles of 95°C 25 s, 57°C 30 s, 72°C 1 min, iii. final elongation – 72°C 5 min. HD Advantage polymerase (Clontech, USA) was used for PCR. Amplification products were sequenced using an ABI PRISM 3130 Genetic Analyzer.

**Statistical analysis**

Statistical importance was calculated by Fisher’s exact test (Statistica v.10.0, StatSoft).

**Results**

The studies using classical cytogenetics showed chromosomal aberrations in 32 (64%) patients. The most common aberrations included deletion of 7q, 5q, 17p, and trisomy of chromosome 8. In 18 (36%) cases no changes in the karyotype were found by conventional karyotyping (cases defined as CN-AML) (Table I). Implementation of the FISH technique allowed for the confirmation of translocation t(15;17) (PML/RARα) in 2 patients; in one patient this aberration was detected only by FISH. Other alterations identified by FISH included: addition of 3q26.1-q26.3 (EV1 gene amplification) in one patient, addition of 8q23-q24.3 (MYC gene amplification) in 1 patient, addition of 11q23 (MLL gene amplification) in 1 patient, and deletion of 17p13.1 (TP53) in 6 (12%) patients (Table I).

Molecular studies of mutations of the FLT3 gene showed the presence of internal tandem duplication in 4 (8%) patients. Studies by numerous authors have shown that this type of mutation is present in 15–35% of patients with AML [14, 22, 23]. The frequency of FLT3 mutations increases with age, but FLT3-ITD in older AML patients (aged 60 and more) has little effect on the outcome, due to the presence of other adverse changes, such as 11q23 rearrangement [1, 11]. In our material, FLT3-ITD mutations occurred in patients aged over 50 years. FLT3-ITD mutation coexisted with a single lesion in the karyotype in 3 patients, it was also found in one patient with a normal karyotype.Falini et al. [24], while examining a group of 591 AML patients, observed that FLT3-ITD mutations occur twice as often in the cases of CN-AML with simultaneous NPM1 mutations than in the cases without this mutation. However, in our material, no coexisting FLT3-ITD and NPM1 gene mutations were observed.

The results of clinical studies have shown a direct correlation between FLT3-ITD mutations and the risk of disease relapse and shorter survival time in AML patients with normal karyotype. In our study, 2 patients (P34 and P35) with internal tandem duplication of FLT3 died during the 3-year follow-up. In acute promyelocytic leukemia (M3 according to FAB subtype), a higher incidence of FLT3 mutations is observed [25]. In our study, FLT3-ITD mutations were found only in patients with AML classified as subtype M1 and M4.

Peng et al., examining a group of 150 AML patients, demonstrated a correlation between the presence of FLT3-ITD mutation and the increased number of leukocytes in blood, increased bone marrow blast cell count and increased activity of lactate dehydrogenase [26]. In addition, they sug-
### Table I. Clinical and molecular characteristics of patients with AML

| No. | Age | Gender | FAB subtype | WBC [G/l] | Survival [months] | Karyotype | FLT3-ITD | NPM1 |
|-----|-----|--------|-------------|-----------|-------------------|-----------|----------|-------|
| 1   | 67  | F      | M4          | 2.63      | 1                 | 41-46,XX,der(3)del(3)(p12),t(3;15)(q27.q15)-,4,del(5)(q15.q35),15,-17,-18,-21,+mar1,+mar2,+mar3,+1-2mar[cp14]/44-47,sl,+19[cp4]/40-41,sl,del(7)[p11][cp2] | -        | -       |
| 2   | 57  | M      | M4          | 12.63     | 123               | 47,XY,8,del(16)(q22)[7]/48,si, +mar1[46,XY,+8,-16[3]/46,XY][10] | -        | -       |
| 3   | 29  | F      | M3          | 0.80      | 4                 | 46,XX[14]/46,XX,del(17)(q17)[14]/46,XX,t(14;17)[q17?q17] | -        | -       |
| 4   | 48  | M      | M4          | 16.10     | 4                 | 36-42,add(X)(q27),+Y,+3,-5,+6,del(7)(q22),add(11)[q275],add(12)[p171],+13,add(17)[p13],+14,-15,-17,-17,-18,-20,del(17)[q75]+del(17)[q75],+der(7)[7;13] | -        | -       |
| 5   | 50  | M      | M1          | 1.50      | 5                 | 82~94,XXYY,2,+mar[cp9]/46,XY[4] | -        | -       |
| 6   | 57  | M      | M4          | 3.90      | 4                 | 46,XY(7)[q10]-,13,-15,+mar1,+mar2[5]/46,XY[8] | -        | -       |
| 7   | 35  | M      | M4          | 11.60     | 8                 | 43-47,XY,3,del(4)[add(4)[p174],add(4)[q275],-5,+add(8)[p1orp21],-10,add(11)[q13],-14,-16,-17,del(17),add(17)[p12],add(17)[q275],-18,-20,-21,-22,+48,mar[p20] | -        | -       |
| 8   | 48  | F      | M5          | 3.74      | 11                | 40~47,XX,del(5)[q13],-8,-17,18,del(20)[q11.2]-21,+mar1,+mar2,1±5mar[cp19] | -        | -       |
| 9   | 21  | F      | M4          | 73.00     | 10                | 46,XX,del(9)[q22][16]/46,XX,-9,+mar[2] | -        | -       |
| 10  | 52  | M      | M6          | 2.20      | 30                | 46,XY | -        | -       |
| 11  | 58  | F      | M2          | 9.58      | 25                | 47~48,XX,6,+mar,9±34,addim[5]/46,XX,4~10,addim[5]/46,XX[3] | -        | -       |
| 12  | 56  | M      | M4          | 39.80     | 34                | 46,XY,add[11][p15][11] | +        | -       |
| 13  | 52  | F      | M5          | 2.41      | 35                | 46,XX | -        | +       |
| 14  | 53  | M      | M1          | 9.60      | 26                | 47,XY,+mar[10]/46,XY[10] | +        | -       |
| 15  | 51  | F      | M4          | 3.22      | 39                | 46,XX | -        | -       |
| 16  | 72  | M      | M5          | 4.50      | 11                | 45,XY,der(1)?del(1)[p32],-7[9]/46,XY[3] | -        | -       |
| 17  | 60  | F      | M5          | 4.48      | 7                 | 45~47,XX,del(15)[q13q33][5],+8[3],+20[4],-21[7]+mar[cp]/46,XX[7] | -        | -       |
| No. | Age | Gender | FAB subtype | WBC [G/l] | Survival [months] | Karyotype | FLT3-ITD | NPM1 |
|-----|-----|--------|-------------|-----------|------------------|-----------|---------|------|
| 18  | 55  | F      | M1          | 33.00     | 11               | 46,XX,-7,+mar[11]/46,XX[6] FISH del TP53 | –  | –    |
| 19  | 64  | M      | M4          | 10.38     | 25               | 36–44,XY,5[14],-12[14],14[6],-15[10],-16[6],-17[10],+22[5],+mar1[14],+mar2[8],+mar3[8],-14mar[12]/46,XY[2] FISH del TP53 | –  | –    |
| 20  | 60  | F      | M3          | 6.20      | 28               | 49,XX,+8,+13,t(15;17)(q22;q21),+21[13]/48,sl,-12[4]/46,XX[3] FISH t(15;17) | –  | –    |
| 21  | 71  | M      | M4          | 5.85      | 28               | 46,XY     | –  | –    |
| 22  | 32  | M      | MO          | 26.30     | 26               | 42,XY,3,-7,-17,+mar1[2]/43–45,XYdel(3)[q21],5,-7,-17,+mar1,1–2mar[cp4] 42–43,XY,-5,-7,add(8)[q24],-21,-22,+mar1,1–2mar[cp15] FISH amp EVI1, del TP53 | –  | –    |
| 23  | 41  | F      | M2          | 25.6      | 36               | 44–45,XX,del(4)[q3?1][13],-10[13],-12[4],add(16)[q24][13],+add16(q24) cp[13]/43–44,XX,der(7)[q11,7][q22][8],del(4)[q27][8],-10[8],-18[4]cp8 | –  | –    |
| 24  | 57  | M      | M4          | 12.50     | 36               | 46,XY     | –  | +    |
| 25  | 74  | M      | M4          | 1.64      | 10               | 47,XY,+21[6]/46,XY[24] | –  | –    |
| 26  | 60  | M      | M4          | 15.10     | 33               | 46,XY     | –  | –    |
| 27  | 38  | M      | M4          | 228.0     | 26               | 46,XY     | –  | +    |
| 28  | 42  | M      | M2          | 7.30      | 25               | 46,XY,t(8;21)[q22;q22][20] | –  | –    |
| 29  | 63  | M      | M4          | 2.76      | 29               | 46,XY     | –  | –    |
| 30  | 48  | M      | M2          | 17.86     | 28               | 45–46,XY,-20,+mar[7]/46,XY[14] | –  | –    |
| 31  | 70  | M      | M1          | 263.7     | 2                | 46,XY,t(10;12)[q24;p13][cp10]/46,XY,del(3)[q21],t(10;12)[q24;p13][5] | –  | –    |
| 32  | 46  | F      | M3          | 21.60     | 24               | 46,XX,t(8;16)[p11;p13][1]/46,sl,(8)[q10][15]/47,slt1,+mar[4] | –  | –    |
| 33  | 46  | F      | M4          | 111.8     | 24               | 46,XX     | –  | –    |
| 34  | 52  | M      | M1          | 36.50     | 1                | 46,XY     | +  | –    |
Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland

### Table I. Cont.

| No. | Age | Gender | FAB subtype | WBC [G/l] | Survival [months] | Karyotype | FLT3-ITD | NPM1 |
|-----|-----|--------|-------------|-----------|-------------------|-----------|---------|-------|
| 35  | 65  | F      | M4          | 409.5     | 9                 | 47,XX,+8[3]/46,XX[27] | +        | –      |
| 36  | 57  | F      | M0          | 2.80      | 24                | 51−55,XX,+1,+der(2)t(2;12)(p11;q11),+6,del(7)(p15),+8,+11,+12,+13,add(17)(p12),+19,+1−3mar[cP]46,XX[2] | –        | –      |
| 37  | 54  | F      | M4          | 2.40      | 24                | 46,XX     | –        | –      |
| 38  | 63  | M      | M4          | 3.54      | 24                | 46,XY     | –        | –      |
| 39  | 71  | F      | M4          | 58.70     | 12                | 45,X,-X[6]/45,XX,-2[5]/46,XX[18] | –        | –      |
| 40  | 45  | M      | M2          | 2.50      | 29                | 46,XY     | –        | –      |
| 41  | 59  | M      | M5          | 4.70      | 5                 | 46,XY     | –        | –      |
| 42  | 60  | M      | M4          | 46.20     | 1                 | 46,XY,t(5;7)(q13;p11),t(X;7)(q13;7)[3]/46,XY[15] | –        | –      |
| 43  | 72  | M      | M4          | 108.9     | 11                | 41−46,X,Y[3],del(7)(p21)[7],add(9)(q22)[4]/46,XX[8],add(9)(q22)[4]/46,XX[3],add(11)(q13)[3]/46,XX[5] | –        | –      |
| 44  | 40  | M      | M4          | 15.00     | 15                | 46,XY     | –        | –      |
| 45  | 36  | F      | M3          | 2.24      | 12                | 46,XX,t(15;17)[q22;q21][15]/46,XX[5] | –        | –      |
| 46  | 39  | M      | M4          | 5.30      | 25                | 46,XY,t(9;22;14) | –        | –      |
| 47  | 54  | M      | M5          | 213.5     | 21                | 46,XY     | –        | –      |
| 48  | 27  | M      | M1          | 21.10     | 25                | 46,XY,del(9)(q22;q22)[16]/46,XY[6] | –        | –      |
| 49  | 31  | M      | M1          | 15.10     | 4                 | 46,XY     | –        | –      |
| 50  | 30  | M      | M0          | 144.2     | 8                 | 46,XY     | –        | –      |
Suggested that FLT3-ITD might be an independent prognostic factor in acute myeloid leukemia [26]. In the current study we observed an increased number of white blood cells in three patients with FLT3-ITD, which confirms their results.

**NPM1**

NPM1 mutations substantially affect the course of AML. They include insertions or deletions resulting in partial or complete loss of tryptophan residues. Abnormal protein encoded by NPM1 changes the location from nuclear to cytoplasmic, which contributes to the development of proliferative disorders [27]. NPM1 mutations are relatively commonly observed in patients with AML. The majority of NPM1 mutations occurring in AML involve exon 12; some rare mutations were described in exons 9, 10 and 11 [28, 29]. The most common type of NPM1 mutation in AML is “type A” mutation, reported in 75–80% of cases [24, 30]. NPM1 mutations in AML patients are associated with normal karyotype (CN-AML) and are rarely found in patients with chromosomal aberrations [19].

In our research, conducted over 3 years, NPM1 mutations were observed in 3 (6%) patients. During the follow-up we did not record deaths in patients with NPM1 mutations. It is known that the presence of NPM1 mutation augurs favorably and is associated with higher rates of complete remission [29]. In patients with CN-AML and NPM1 mutations, relapse-free survival is longer in comparison with what we observed in patients with NPM1 mutations [1].

Backer et al. in 2010, studying a group of 148 patients aged ≥ 60 years, found that the prognostic significance of NPM1 mutations increases with age, especially in older patients. Those patients who have a mutation in NPM1, especially without concomitant FLT3-ITD mutation, show significantly better prognosis than patients without mutations in the NPM1 gene [31]. Similar conclusions have been presented by many authors [32, 33].

In our study, we observed the occurrence of mutations in this gene only in patients with normal karyotype, and their average age was 49 years.
NPM1 mutation is usually present throughout the leukemic cell population, demonstrating its essential role in carcinogenesis [24]. It is stable in the course of the disease and its presence is detected also at relapse even a few years after the initial diagnosis [34]. Mutation reversion is extremely rare and sometimes is associated with a change in karyotype [18, 19, 34].

Coexistence of NPM1 and FLT3-ITD mutations is relatively common, found in approximately 18% of patients with CN-AML [35]. Thiede et al. [19] found that in patients with NPM1 and co-existing FLT3-ITD, the NPM1 mutation preceded the occurrence of FLT3-ITD.

In our study group, patients carrying both FLT3-ITD and exon 12 NPM1 mutation were not found. The studies by Schneider et al. [36] in a group of 1321 patients with CN-AML showed the lower incidence of FLT3-ITD and NPM1 mutation with age in adult patients. Furthermore, lack of mutations in NPM1 and FLT3-ITD in the elderly suggested that other molecular and clinical risk factors might influence the outcome in this age group.

Our findings in a relatively small group of AML patients from southeast Poland confirm other reports of a better prognosis for CN-AML patients with NPM1 mutation. In the case of our patients with FLT3-ITD mutation its association with older age and shorter survival time was also confirmed. As the incidence of both mutations in our study group was lower as compared to other reports, studies on larger cohorts are required to confirm these results.

Acknowledgments

This project was supported by the National Center of Science (NCN) grant NN 402187035 to DK. This project was supported by the National Center of Science (NCN) grant NN 402187035 to DK and grant MNmb 232 to Szymon Zmorzyński.

Conflict of interest

The authors declare no conflict of interest.

References

1. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010; 115: 453-74.
2. Estey EH, Döhner H. Acute myeloid leukemia. Lancet 2006; 368: 1894-907.
3. Grimwade D, Mrózek K. Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. Hematol Oncol Clin North Am 2011; 25: 1135-61.
4. Betz BL, Hess JL. Acute myeloid leukemia diagnosis in the 21st century. Arch Pathol Lab Med 2010; 134: 1427-33.
5. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are reductive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia. Blood 2002; 100: 4325-36.
6. Mrózek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukemia. Best Pract Res Clin Haematol 2001; 14: 19-47.
7. Mrózek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2006; 169-77.
8. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2003; 82-101.
9. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-42.
10. Bacher U, Schnittger S, Haferlach T. Molecular genetics in acute myeloid leukemia. Curr Opin Oncol 2010; 22: 646-55.
11. Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol Educ Program 2010; 47-55.
12. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination maters – an analysis of 3082 patients. Blood 2008; 111: 2527-37.
13. Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 2012; 30: 735-41.
14. Dalenc F, Drouet J, Ader I, et al. Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells. Int J Cancer 2002; 100: 662-8.
15. Yu Y, Maggi LB Jr, Brady SN, et al. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol 2006; 26: 3798-809.
16. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437: 147-53.
17. Grisendi S, Micucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6: 493-505.
18. Falini B, Gionfriddo I, Cecchetti F, Ballanti S, Pettirossi V, Martelli MP. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy? Blood Rev 2011; 25: 247-54.
19. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011-20.
20. Libura M, Filip AA, Haus O. Molecular diagnostics of acute myeloblastic leukemia. In: Molecular aspects of hematologic malignancies. Witt M, Dawidowski M, Szczepański T (eds). Springer-Verlag, Berlin, Heidelberg 2012.
21. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106: 3740-6.
22. Okuwaki M, Matsumoto T, Tsujimoto M, Nagata K. Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett 2001; 506: 272-6.
23. Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem 2000; 275: 24451-7.
24. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with normal karyotype. N Engl J Med 2005; 352: 254-66.
25. Smith ML, Hills RK, Grimwold D. Independent prognostic variables in acute myeloid leukemia. Blood Rev 2011; 25: 39-51.
26. Peng HL, Zhang GS, Gong Fl, et al. Fms-like tyrosine kinase (FLT) 3 and FLT3 internal tandem duplication in different types of adult leukemia: analysis of 147 patients. Croat Med J 2008; 49: 650-9.
27. Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukemia with mutated NPM1: mechanism and clinical implications. Leukemia 2009; 23: 1731-43.
28. Cazzaniga G, Lio Nigro L, Cifola I, et al. Simultaneous occurrence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Leukemia 2009; 23: 199-203.
29. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukemia: towards definition of a new leukemia entity. Hematol Oncol 2009; 27: 171-81.
30. Mrózek K, Baldus CD, Marcucci G, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for prognostically prioritized molecular classification? Blood 2007; 109: 431-48.
31. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression signatures: a cancer and leukemia group B study. J Clin Oncol 2010; 28: 596-604.
32. Park BG, Chi HS, Jang S, et al. Association of cup-like nuclei in blast with FLT3 and NPM1 mutations in acute myeloid leukemia. Ann Haematol 2013; 92: 451-7.
33. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-18.
34. Meloni G, Mancini M, Gianfelici V, Martelli MP, Foa R, Falini B. Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. Haematologica 2009; 94: 298-300.
35. Mrózek K, Marucci G, Paschka P, Bloomfield CD. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 2008; 20: 711-18.
36. Schneider E, Hoster E, Schneider S, et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Haematol 2012; 91: 9-18.